Log In
BCIQ
Print this Print this
 

neratinib intravenous (PB272)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionIntravenous formulation of HER1, HER2 and HER4 kinases inhibitor
Molecular Target Epidermal growth factor receptor 1 (EGFR1) (HER1) (ErbB1) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionEpidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor; Epidermal growth factor (EGF) receptor 1 (HER1) (ErbB1) inhibitor; Epidermal growth factor (EGF) receptor 4 (HER4) (ErbB4) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer
Regulatory Designation
PartnerPuma Biotechnology Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today